

1 **Large-scale genome-wide analyses with proteomics integration reveal novel loci and**
2 **biological insights into frailty**

3
4 Jonathan K.L. Mak^{§1,2}, Chenxi Qin^{§1}, Anna Kuukka³, FinnGen⁴, Sara Hägg¹, Jake Lin^{*1,3} Juulia
5 Jylhävä^{*1,5}

6 [§]shared first authorship; ^{*}shared last authorship

7
8 ¹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

9 ²Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of
10 Hong Kong, Hong Kong, China

11 ³Health Sciences, Faculty of Social Sciences, Tampere University, Tampere, Finland

12 ⁴Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Tukholmankatu
13 8, 00290 Helsinki, Finland

14 ⁵Health Sciences and Gerontology Research Center (GEREC), Faculty of Social Sciences, Tampere
15 University, Tampere, Finland

16
17 Correspondence to:

18 Juulia Jylhävä, PhD
19 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
20 Email: juulia.jylhava@ki.se

21 **Abstract**

22
23 Frailty is a clinically relevant phenotype with significant gaps in our understanding of its
24 etiology. We performed a genome-wide association study of frailty in FinnGen (N=500,737) and
25 replicated the signals in the UK Biobank (N=429,463) using polygenic risk scores (PRSs). We
26 prioritized genes through proteomics integration (N~45,000; UK Biobank) and colocalization of
27 protein quantitative trait loci. Frailty was measured using the Hospital Frailty Risk Score (HFRS).
28 We observed 1,588 variants associated with frailty ($p < 5 \times 10^{-8}$) of which 1,242 were novel, i.e.,
29 previously unreported for any trait. The associations mapped to 106 genes of which 31 were
30 novel. PRS replication validated the signals ($\beta = 0.074$, $p < 2 \times 10^{-16}$). Cell type enrichment analysis
31 indicated expression in neuronal cells. Protein levels of *KHK*, *CGREF1*, *MET*, *ATXN2*, *ALDH2*,
32 *NECTIN2*, *APOC1*, *APOE* and *FOSB* were associated with HFRS, whereas colocalized signals
33 were observed within *APOE* and *BRAP*. Our results reveal novel genetic contributions and causal
34 candidate genes for frailty.

35 **Main**

36 Aging is a highly complex process with substantial heterogeneity in health trajectories among
37 individuals. Frailty represents a clinically relevant aging phenotype that gauges health in aging¹
38 and predicts various adverse outcomes independent of chronological age². Frailty describes a
39 syndrome of decreased physiological reserves across multiple homeostatic systems¹. Currently, no
40 gold standard exists to measure frailty; instead, several scales with different properties have been
41 developed, each capturing partially different at-risk populations³. Created based on 109 weighted
42 International Classification of Diseases, 10th Revision (ICD-10) codes characterizing older adults
43 with high resource use and diagnoses associated with frailty, the Hospital Frailty Risk Score
44 (HFRS) presents a relatively new scale to measure frailty⁴. It has a fair overlap with existing frailty
45 definitions based on the deficit accumulation (frailty index [FI]) and phenotypic (frailty phenotype
46 [FP]) models of frailty and has a moderate agreement with the FI⁴.

47 The etiology of frailty remains incompletely understood. Twin studies by us and others
48 suggest that frailty, measured using the FI, is up to 52% heritable^{5,6}, with relatively stable genetic
49 influences across age⁷. To date, only two previous large-scale genome-wide association studies
50 (GWASs) of frailty exist. Atkins et al. performed a meta-analysis GWAS of FI identified 34 loci
51 and estimated the single nucleotide polymorphism (SNP) heritability of the FI at 11%⁸. Ye et al.
52 identified 123 loci for FP and estimated the SNP heritability of the FP at 6%⁹. It is however likely
53 that additional genetic signals exist and analyses in other large populations can shed further light
54 on the genetic underpinnings of frailty.

55 To the best of our knowledge, no previous studies into the genetics of frailty using HFRS
56 as the definition exist. To this end, we set out to perform a GWAS of the HFRS in the FinnGen
57 sample (N=500,737), with replication of the signals in using a polygenic risk score of the HFRS in

58 the UK Biobank (N=429,463). As dementia has the highest weight in the HFRS definition, we
59 performed a sensitivity the analysis by removing the contribution of dementia from the HFRS. A
60 functional follow up to identify causal genetic loci was performed through integration of measured
61 protein levels in the UK Biobank (N up to 44,678) and a colocalization analysis of protein
62 quantitative trait locus (pQTL)¹⁰.

63

64 **Results**

65 *Sample characteristics*

66 The workflow of the analyses is presented in **Figure 1**. In the HFRS GWAS and subsequent PRS
67 analyses, we included 500,737 (282,202 females, 56.4%) FinnGen participants and 429,463 UK
68 Biobank participants (232,380 females, 54.1%) of European descent (white British).
69 Characteristics of the study populations are presented in **Table 1**.

70

71 *GWAS of HFRS*

72 We identified 1,588 variants associated ($p < 5 \times 10^{-8}$) with the HFRS in the main analysis and 492
73 variants in the sensitivity analysis removing the dementia weights from the HFRS (**Figure 2a & b**;
74 **Supplementary Tables 1 & 2**). As dementia diagnosis has the highest weight in the HFRS formula,
75 the most influential peak expectedly resided in the *APOE* (rs7412) region on chromosome 19
76 (**Figure 2a**). Sensitivity analysis confirmed the expected loss of the *APOE* peak (**Figure 2b**). Of
77 the 1,588 and 492 variants associated with HFRS and HFRS without dementia, 1,242 and 440,
78 respectively, were novel with respect to the GWAS Catalog and previously reported GWAS results
79 on the FI⁸, FP⁹ and mvAge¹¹ (**Supplementary Tables 1 & 2**). The variants mapped to 106 and 50
80 genes of which 31 and 8 were novel, i.e., previously unreported for any trait at $p < 5 \times 10^{-8}$, also

81 revealing unique (non-shared) associations in both analyses (**Figure 3a, Supplementary Tables 1**
82 **& 2**). The overlap between our findings and previous GWAS on frailty and mvAge is presented
83 individually for each GWAS gene set in **Supplementary Figure 1**.

84

85 *Genetic correlation and heritability*

86 We observed a lambda genomic control value of 1.27 with an intercept of 1.19 (standard error
87 [SE]=0.011) for HFRS and 1.11 with an intercept of 1.23 (SE=0.010) for HFRS without dementia
88 (QQ plots provided in **Supplementary Figure 2**). Despite the relatively high lambda values, the
89 intercepts suggest that the inflation in test statistics was mainly due to polygenicity, rather than bias
90 due to population stratification. The single nucleotide variant (SNP) heritability was 0.06
91 (SE=0.002) for HFRS and 0.04 (SE=0.002) for HFRS without dementia. Statistically significant
92 and positive genetic correlations ($p < 2.2 \times 10^{-16}$) were observed between HFRS and previous
93 GWASs on frailty and mvAge (**Figure 3b**).

94

95 *Cell type and pathway enrichment*

96 For HFRS, the top ($p < 3.7 \times 10^{-5}$, corrected for multiple testing) cell types enriched for expression
97 were limbic system neurons in cerebrum, excitatory neurons (Ex6) in visual cortex,
98 oligodendrocyte precursor cells (OPCs) in cerebellar hemisphere and oligodendrocytes in
99 cerebellum (**Supplementary Figure 3 & Supplementary Table 3**). For HFRS without dementia,
100 the top cell types were OPCs and astrocytes in cerebellar hemisphere, skeletal muscle satellite cells
101 in muscle, endocrine cells in stromal cells in stomach (**Supplementary Figure 4 &**
102 **Supplementary Table 4**). Enrichr¹² pathway analysis (adjusted $p < 0.05$) showed that the top
103 pathways for HFRS functions relevant to the nervous system (Herpes simplex virus 1 infection,
104 Netrin Mediated Repulsion Signals), cell adhesion and lipid metabolism (**Supplementary Table**

105 5). For HFRS without dementia, none of the pathways were significant after multiple testing
106 correction (**Supplementary Table 6**).

107

108 *Exploring potentially causal and functional variants through proteomics integration*

109 To identify potentially causal and functional variants (i.e., missense, splice region, loss of
110 function and 5' and 3' untranslated region [UTR] variants associated with the HFRS and HFRS
111 without dementia at $p < 5 \times 10^{-7}$) (**Supplementary Tables 7–8**), we associated the protein levels of
112 the corresponding prioritized genes to HFRS (13 proteins available in UK Biobank Olink
113 platform) and HFRS without dementia (8 proteins available in UK Biobank Olink platform).
114 After adjusting for birth year, sex, and the first 10 principal components (PCs), 9/13 (KHK,
115 CGREF1, MET, ATXN2, ALDH2, NECTIN2, APOC1, APOE and FOSB) and 2/8 (CDK and
116 POF1B) proteins were significantly associated with the HFRS and HFRS without dementia,
117 respectively, at a false discovery rate (FDR) < 0.05 (**Figure 4 & Supplementary Table 9**).

118

119 *Colocalization analysis*

120 We further conducted pQTL colocalization analyses for the 24 loci identified for HFRS and 15 loci
121 identified for HFRS without dementia GWASs (**Supplementary Tables 10 and 11**). A total of 20
122 loci for HFRS and 9 loci for HFRS without dementia had enough power for the analyses (posterior
123 probability > 0.88 , see Methods). Of them, the colocalized signal (i.e., shared single causal variant,
124 $H4 < 90$, see Methods) was detected within *APOE* and *BRAP* genes for HFRS (**Supplementary**
125 **Table 10**), whereas no colocalized signal was detected within genes for HFRS without dementia.
126 For most of the tested genes, the $H3$ values were greater than or close to 90, indicative of distinct
127 causal variants for protein levels and HFRS (**Supplementary Tables 10 and 11**). Regional

128 association plots of the *APOE* gene demonstrated that the strongest signal peak rs429358 and
129 variants in high LD with it fall in the vicinity (**Supplementary Figure 5A**).

130
131 *HFRS PRS analyses in FinnGen and UK Biobank: early-onset frailty and outcome prediction*
132 The PRS of the HFRS (PRS-HFRS) was associated with HFRS in the full sample of the UK
133 Biobank ($\beta=0.074$ per SD increase; $p<2\times 10^{-16}$) after adjusting for birth year, sex, smoking and first
134 10 PCs (**Figure 5a**). Next, using similar adjustments, we analyzed whether the HFRS-PRS could
135 predict early-onset frailty i.e., HFRS>5 before age 65, and observed an odds ratio of 1.25 ($p<2\times 10^{-$
136 16) in the sample of all self-identified whites of the UK Biobank (**Figure 5b**). The estimates of the
137 HFRS-PRS were essentially similar in men and women compared to the full sample across all
138 analyses (**Figure 5a–d**). The numeric results of all the HFRS-PRS analyses are presented in
139 **Supplementary Table 14**. Lastly, we examined whether the HFRS-PRS predicts all-cause
140 mortality and number of hospitalizations and found significant associations with both outcomes
141 (**Figure 5c and d**); adjusting for the HFRS-PRS based on a crude model with age and sex improved
142 model performances (**Supplementary Table 11**).

143
144 **Discussion**

145 Our results represent the largest GWAS of frailty to date and the first GWAS of frailty assessed
146 through the HFRS, revealing 1,588 variants, of which 1,242 were novel i.e., previously unreported
147 for any trait. The variants mapped to 106 genes, of which 31 were novel and highlights that the
148 genetic etiology of frailty is largely unrelated to previously known disease risk variants. Protein
149 levels of *KHK*, *CGREF1*, *MET*, *ATXN2*, *ALDH2*, *NECTIN2*, *APOC1*, *APOE* and *FOSB* were

150 associated with HFRS, whereas colocalized signals were observed within *APOE* and *BRAP*.
151 Enriched expression of the associated genes was observed in various neuronal cells, also when the
152 contribution of dementia was removed from the frailty definition. Using the HFRS-PRS, we
153 replicated the genetic signals in an independent sample (UK Biobank) and validated our findings
154 ($\beta=0.074$, $p<2\times 10^{-16}$). The HFRS-PRS also predicted early-onset frailty as well as all-cause
155 mortality and number of hospitalizations.

156 The strongest GWAS signals were observed in the *TOMM40/APOE/APOC1/NECTIN2*
157 locus on 19q13.3, a locus in strong LD and known for its associations with cognitive¹³ and
158 cardiometabolic¹⁴ traits. We observed the strongest signal for the missense variant rs429358
159 (388 T > C) that together with rs7412 defines the *APOE* $\epsilon 2$, $\epsilon 3$, and $\epsilon 4$ haplotypes. The rs7412 was
160 however not associated with frailty in our study. A similar pattern of finding has been observed for
161 longitudinal weight loss – a feature that also characterizes frailty – where rs429358 increased the
162 risk, while rs7412 did not¹⁵. Previous studies have shown that this locus is pleiotropic, such that
163 rs429358 influences cognitive traits, while rs7412 controls plasma lipid levels¹⁶. We did
164 nevertheless identify lipid-level-increasing variants, such as the *APOC1* rs4420638 (G allele)¹⁷
165 associated with frailty, but lipid-associated variants were not abundant in our signals. Our
166 sensitivity analysis removing the contribution of dementia from the HFRS truncated the
167 chromosome 19 peak as expected and revealed additional loci. Of the 106 genes identified for
168 HFRS, 16 were shared with HFRS without dementia, while 34 genes were unique to HFRS without
169 dementia. Genetic correlation between HFRS and HFRS without dementia was nevertheless almost
170 perfect (0.98), indicating the same underlying genetic construct.

171 Intersecting the HFRS-associated signals with previous frailty GWASs of FI⁸ and FP⁹
172 revealed a negligible overlap. Genetic correlations between HFRS, FI and FP were nevertheless

173 moderate, ranging from 0.54 to 0.63. We estimated the SNP heritability of HFRS at 6%, an estimate
174 in the same range as previously reported for the FI (11%)⁸ and FP (6%)⁹. In our previous study¹⁸,
175 we assessed the phenotypic correlation between HFRS and FI at 0.21 and HFRS and FP at 0.31 in
176 the UK Biobank participants, indicating somewhat lower than phenotypic correlations compared
177 to their genotypic counterparts. These findings thus suggest that while the different
178 operationalizations of frailty share their genetic etiologies to a significant extent, environmental
179 risk factors and relevant interactions contributing to the expression of frailty may differ.

180 Cell type enrichment indicated enriched expression of the genes associated with the signals
181 in various neuronal cells, such as limbic system and excitatory neurons, OPCs and
182 oligodendrocytes located in the cerebrum, visual cortex, cerebellar hemisphere and cerebellum,
183 respectively. Enrichment of OPCs (cerebellar hemisphere) persisted also after removing the
184 contribution of dementia diagnoses from the HFRS. Expression enrichment in brain tissues was
185 likewise observed in our previous GWAS of FI⁸ in which we identified frontal cortex BA9,
186 cerebellar hemisphere, spinal cord cervical c-1 and hippocampus as significant. The GWAS on FP⁹
187 by Ye et al. also identified their genetic signals enriched in brain tissues, such as cerebellar
188 hemisphere, frontal cortex BA9 and cerebellum. What is noteworthy is that neither FI or FP include
189 any items of cognition or dementia diagnosis in the frailty definition. Our findings thus reinforce
190 the role of central nervous system functions in frailty, regardless of the definition. The previous FI
191 and FP GWAS signals were also enriched in inflammatory mechanisms or pathways^{8,9}, a finding
192 not observed by us with the exception of the Herpes simplex virus 1 infection pathway. Our
193 pathway analyses instead highlighted cell adhesion and lipid metabolism relevant to the signals.
194 Our results included several cell adhesion molecules, such as *CNTNAP2*, *CADMI*, *NCAMI*, *PVR*,
195 *NECTIN2*, suggesting novel contributions to frailty. While cell adhesion molecules mediate the

196 transport of leukocyte migration towards the inflammation site¹⁹, previous results linking cell
197 adhesion directly to frailty are scarce, except for the association of circulating ICAM-1 with
198 frailty²⁰.

199 The protein level associations of the potentially functional variants with frailty revealed the
200 largest effect sizes for *CGREF1*, *NECTIN2*, *MET* and *APOC1*, with elevated levels of the former
201 two and lower levels of the latter two associating with higher HFRS score. *CGREF1* is a secretory
202 cell growth regulator whose involvement in disease is currently unknown. A previous GWAS has
203 however demonstrated associations of *CGREF* variants with plasma lipids²¹. *NECTIN2*, a cell
204 adhesion molecule and mediator of viral entry into neuronal cells has been linked to Alzheimer's
205 disease²² and plasma lipid profiles²¹ in previous GWASs. Elevated serum levels of *NECTIN2* have
206 been reported in colorectal cancer²³. *MET* is a proto-oncogene and a receptor tyrosine kinase with
207 previous GWAS findings on body height and liver enzymes²⁴ but limited evidence on genetic
208 disease associations. We found that lower plasma levels of *APOC1* and *APOE* were associated with
209 greater frailty, a finding that is in line with previous results on low *APOE* levels associated with
210 progression of cognitive impairment²⁵ and dementia-related mortality²⁶. Findings on all-cause,
211 cardiovascular and cancer mortality and *APOE*²⁶, and hyperlipidemia and *APOC1*²⁷, nevertheless
212 demonstrate higher levels of these proteins associated with increased risks, indicating pleiotropic
213 functions of these proteins. When the dementia weights were removed from the HFRS, higher
214 plasma levels of *CDK1* and *POF1B* were associated with greater frailty. Previous findings on
215 variants in these genes are limited to height²⁸ and bone mineral density²⁹ for *CDK1* and
216 velopharyngeal dysfunction³⁰ for *POF1B*. Results from the pQTL colocalization analysis suggest
217 that the same causal variants in *APOE* and *BRAP*, a *BRCA1* associated protein, underlie the protein

218 level and HFRS. Most tested genes nevertheless showed distinct causal variants for the proteins
219 and HFRS.

220 Replication of the GWAS signals through the HFRS-PRS in the UK Biobank validated the
221 results, including individually for men and women. We also showed that the HFRS-PRS can
222 identify individuals at risk of early-onset frailty. As frailty manifests relatively late in life for most
223 individuals, risk assessment through PRS may offer possibilities for early intervention to mitigate
224 frailty before it escalates where prevention is still effective. PRSs of various age-related phenotypes
225 associated with negative outcomes, such as frailty, epigenetic clocks and functional capacity could
226 perhaps be jointly considered to yield more robust predictions. Future studies are however needed
227 to ascertain the clinical utility of such approaches.

228 This study has several strengths, the most notable being the large sample size, equaling to
229 ~1 million participants. Functional follow-up through proteomics integration provided additional
230 insight into the roles of the identified genes in frailty. Our definition of frailty was based on clinical
231 diagnoses in register data; such an approach has both advantages and disadvantages. A notable
232 advantage is that in Finland and the UK, public healthcare is primarily tax-funded, and each citizen
233 has equal access. With a diagnosis-based ascertainment of frailty, issues pertinent to self-reported
234 data, such as recall bias and missing information were avoided. On the other hand, some conditions
235 may be underreported in the registers, while others may have a lag from the onset of symptoms to
236 assigning the diagnosis. We also note that the HFRS-PRS associations were weaker in the UK
237 Biobank compared to FinnGen, a finding likely explained by healthy selection due to volunteer-
238 based participation to the UK Biobank compared to FinnGen that consists of national cohorts and
239 biobank samples of hospitalized individuals. Also pertinent to all GWASs, the discovery samples

240 tend to have stronger association statistics compared to replication, a phenomenon known as the
241 winner's curse.

242 In conclusion, our results provide the first GWAS on HFRS and reveal novel genetic
243 contributions and causal candidate genes. Our results also highlight previously unreported
244 associations between cell adhesion molecules and frailty. Overall, the results reinforce previous
245 findings that central nervous functions are relevant to the etiology of frailty, regardless of how
246 frailty is defined.

247

248 **Methods**

249 *Samples*

250 FinnGen is a large national genetic resource (N=520,210; Release 12) established in 2017 and
251 consisting of Finnish individuals, aged 18 years and older at study baseline³¹. FinnGen includes
252 prospective epidemiological and disease-based cohorts as well as hospital biobank samples.
253 Information on diagnoses since 1969 was linked by the unique national personal identification
254 number to national healthcare, population and cause of death registries and recorded using the ICD
255 Revisions 8–10. Information on dates and causes of death were obtained via linkages to the
256 population and cause of death registers through (September 30, 2023, R12 v1). After excluding
257 individuals with missing information on baseline age, birth year and sex, and samples not passing
258 genotyping quality control (see below), we included 500,737 FinnGen participants in this study.

259 The UK Biobank includes 502,642 volunteer participants, aged 37 to 73 years old at
260 baseline, recruited through 22 assessment centers across England, Scotland and Wales between
261 2006 and 2010³². The participants provided self-reported information on demographics, lifestyle
262 and disease history via questionnaire and underwent physiological measurements, including

263 providing a blood sample for genetics data. Hospital inpatient data were sourced from the Hospital
264 Episode Statistics containing electronic medical records (i.e., ICD-10 codes) for all hospital
265 admissions to National Health Service hospitals in England through December 31, 2022. Death
266 register data covered all deaths in the population through December 31, 2022, including primary
267 and contributory causes of death. Ethics statements of FinnGen and UK Biobank are presented in
268 Supplementary methods.

269
270 *Assessment of frailty*

271 The HFRS was calculated according to a previously described protocol⁴ based on 109 weighted
272 ICD-10 codes, such that each code was assigned with a weight ranging from 0.1 to 7.1 according
273 to the strength of the association with frailty (**Supplementary Table 12**). The HFRS score was
274 then calculated by summing up all the weights and used as a continuous variable in the GWAS.
275 We also categorized the HFRS into low (<5), intermediate (5–15) and high (>15) risk of frailty as
276 previously described⁴ and used the cut points to describe frailty in our study populations. In the
277 main analysis, we included all available ICD-10 codes for each person from age 30 years to the
278 age at the end of follow-up to calculate the HFRS. As dementia diagnoses have the highest weight
279 in the HFRS, we calculated the HFRS also by excluding dementia weights from the formula and
280 performed all analyses, except for PRS associations, using the HFRS without dementia.

281
282 *Genotyping and imputation*

283 Genotyping in FinnGen was performed on Illumina (Illumina Inc., San Diego, CA) and custom
284 AxiomGT1 Affymetrix (Thermo Fisher Scientific, Santa Clara, CA) genome-wide arrays and
285 imputed to 16,387,711 (INFO > 0.6) variants using a population-specific SISu v.3 imputation
286 reference panel as previously described³³. Individuals with ambiguous sex and non-Finnish

287 ancestry were excluded. UK Biobank samples (v3 genotyping release) were genotyped on custom
288 Affymetrix microarrays and imputed using the 1000 Genomes and the Haplotype Reference
289 Consortium reference panels to ~93M variants³⁴. Participants were excluded if they were flagged
290 as having unusually high heterozygosity or missing genotype calls (<5%). Our analysis was
291 restricted to white British participants (N=429,463). Detailed procedures on genotype calling,
292 quality controls and imputation have been previously described for FinnGen³¹ and UK Biobank³⁴.

293

294 *GWAS*

295 The analytical pipeline for GWAS and post-GWAS analyses is presented in **Figure 1**. We first
296 performed a GWASs of HFRS in FinnGen using the SAIGE³⁵ (v0.35.8.8) software, which uses
297 linear mixed-effects modeling to account for genetic relatedness and confounding by ancestry³⁶.
298 We included variants (N=21,294,561) with minor allele frequency >0.01%, Hardy-Weinberg *p*-
299 value >1×10⁻⁹ and imputation INFO score ≥0.9. The models were adjusted for birth year, birth
300 region, sex and the 10 first PCs. HFRS was inverse normal transformed prior to modeling. The
301 genome-wide significance level was set to 5×10⁻⁸. Using the GWAS Catalog and results of previous
302 GWASs into frailty (using the FP⁹ and FI⁸ to measure frailty) and mvAge¹¹, a genomic structural
303 equation modeling-derived composite construct of healthspan, parental lifespan, extreme
304 longevity, frailty and epigenetic aging, we assessed the number of novel and previously unreported
305 associations.

306

307 *Genetic correlation and heritability*

308 Using linkage disequilibrium score regression³⁷ (v1.0.1) and LD merged with the HapMap3
309 reference panel of ~1.1 million variants, we estimated 1) the potential bias from e.g. population

310 stratification and cryptic heritability in the GWAS results, 2) heritability of HFRS and 3) genetic
311 correlations between HFRS and previous GWASs of FI⁸, FP⁹ and mvAge¹¹. As the FI GWAS⁸ used
312 an opposite effect allele compared to the standard FinnGen workflow, we inverted the genetic
313 correlation coefficient to facilitate interpretation.

314
315 *Functional annotation: cell type and pathway enrichment*

316 To explore tissue and cell type specificity of the annotated genes underlying HFRS, we applied
317 WebCSEA, a web platform to derive context-specific expression patterns of genes underlying
318 complex traits, encompassing the Human Cell Atlas and single cell data resources³⁸. Enrichr
319 pathway analysis¹² based on KEGG³⁹, Reactome⁴⁰ and WikiPathway⁴¹ resources, was applied to
320 explore enriched pathways (FDR<0.05) of the identified genes (GWAS $p < 5 \times 10^{-8}$).

321
322 *Proteomics integration*

323 To prioritize genes and identify potentially functional and causal variants, we narrowed down the
324 association signals to a smaller number of missense, splice region, loss of function and 5' and 3'
325 UTR variants (the two last mentioned potentially affecting transcript stability, localization and
326 signal response) identified from the Variant Effect Predictor pipeline⁴², that were associated with
327 the HFRS at a slightly more relaxed threshold ($p < 5 \times 10^{-7}$). Using the Olink proteomics data, we
328 then examined if the protein levels of the variants (at a gene level resolution) were associated with
329 HFRS in the UK Biobank. Details of the UK Biobank Olink proteomics assay, quality control and
330 data processing procedures have been described elsewhere⁴³. Briefly, ~50,000 UK Biobank
331 participants were randomly selected for the proteomics profiling using EDTA plasma samples
332 collected at the baseline assessment. A total of 2,923 proteins was measured across 8 protein panels
333 using the antibody-based Olink Explore 3072 platform. Protein levels were measured in normalized

334 Protein eXpression (NPX) values, which represent the relative concentration of proteins on a log-
335 2 scale. All the protein levels were scaled to mean=0 and SD=1 before the association testing.
336 Linear regression models were then performed to assess the association between the proteins that
337 were available in the Olink platform and HFRS, adjusting for birth year, sex, and the first 10 PCs.
338 We considered an FDR<0.05 as statistically significant in the proteomics analysis.

339
340 *Colocalization analyses*
341 To further prioritize the genes, we summarized gene loci to which the genome-wide significant or
342 potential functional variants were mapped (**Supplementary Tables 1, 2, 7 & 8**). We performed a
343 Bayesian-based colocalization analysis for each locus, using a flanking window of 1Mb and default
344 parameters for prior probabilities¹⁰. The analysis assumes that only one causal variant exists for
345 each trait in a genomic locus and returns posterior probabilities indicating the likelihood that the
346 following hypotheses (H) are true: there is no association at the locus with either protein level or
347 HFRS (H0); there is an association with protein level but not HFRS (H1); there is no association
348 with protein level but there is an association with HFRS (H2); there is an association with both the
349 protein level and HFRS but with distinct causal variants (H3); there is an association with both the
350 protein level and HFRS with a shared causal variant (H4). We considered the analysis having
351 enough power if the sum posterior probabilities of having a distinct or shared causal variant
352 exceeded 88%. A colocalized signal was detected if the posterior probability of a shared causal
353 variant (H4) existence was greater than 90%.

354
355 *PRS analyses*
356 Using the GWAS summary statistics from FinnGen, we calculated the PRS for HFRS by applying
357 PRS with continuous shrinkage⁴⁴ (PRS-CS) and using the European panel from the 1000

358 Genomes⁴⁵ LD reference, where ~1.1 million variants were selected. All the PRS analyses were
359 performed in FinnGen (the discovery sample) for reference and replicated in the UK Biobank.
360 Using linear regression, we fitted linear model to assess how the HFRS-PRS associates with the
361 HFRS. HFRS was considered as a standardized z-score in the linear regressions. We also performed
362 logistic regressions to assess the associations of the HFRS-PRS with early-onset frailty, defined as
363 HFRS >5 before age 65. The PRS was modeled as per SD change and all the models included birth
364 year, birth region (FinnGen), sex and the first 10 PCs as covariates.

365 Lastly, as frailty manifests in late life for most individuals, we asked whether the HFRS-
366 PRSs could be used in early risk stratification to identify individuals at risk of adverse outcomes.
367 To this end, Cox models with attained age as the timescale and linear regression models were fitted
368 to assess whether the HFRS-PRS predicts all-cause mortality and number of hospitalizations,
369 respectively. The added value of the HFRS-PRS beyond age and sex in the prediction was assessed
370 using the F-test for linear regressions and likelihood ratio test for Cox models. The number of
371 hospitalizations was scaled to a mean=0 and SD=1 prior to modeling.

372

373 **Data availability**

374 Individual-level data cannot be stored in public repositories or otherwise made publicly available
375 due to ethical and data protection restrictions. However, data are available upon request for
376 researchers who meet the criteria for access to confidential data. Data from the UK Biobank are
377 available to bona fide researchers upon application at [https://www.ukbiobank.ac.uk/enable-your-](https://www.ukbiobank.ac.uk/enable-your-research)
378 [research](https://www.ukbiobank.ac.uk/enable-your-research). FinnGen results, according to FinnGen consortium agreement, are subjected to one year
379 embargo and summary statistics are then made available to the scientific community and release
380 two times a year. Information on accessing FinnGen data can be found at
381 https://www.finnngen.fi/en/access_results.

382

383

384

385 **Code availability**

386 All the data processing, visualization, and statistical analyses were performed using Python 3.8
387 (2.7 for LDSC) and R v.4.3.2 (R Foundation for Statistical Computing, Vienna, Austria;
388 <https://www.r-project.org/>). Venn diagrams were created using the R package *ggvenn* (version
389 0.1.10; <https://cran.r-project.org/web/packages/ggvenn/index.html>). Correlation plots were created
390 using the R package *corrplot* (v.0.92; <https://cran.r-project.org/web/packages/corrplot/index.html>).
391 Forest plots were created using the R package *ggforestplot* (v.0.1.0;
392 <https://nightingalehealth.github.io/ggforestplot/>). R codes used to create the figures are available
393 from the authors upon request.

394

395 **Acknowledgements**

396 This work was supported by the Swedish Research Council (grant no. 2018-02077 to JJ, 2019-
397 01272, 2020-06101, 2022-01608), the Research Council of Finland to JJ (grant no. 3493358), the
398 Sigrid Jusélius Foundation to JJ, the Yrjö Jahnsson Foundation to JJ (grant no. 20217416),
399 Instrumentarium Science Foundation to JJ and Signe and Ane Gyllenberg Foundation to JJ (grant
400 no. 6226). This research was conducted using the UK Biobank resource, as part of the registered
401 project 22224. The analyses of UK Biobank genotypes were enabled by resources in project
402 sens2017519 provided by the National Academic Infrastructure for Supercomputing in Sweden
403 (NAISS) at UPPMAX, funded by the Swedish Research Council through grant agreement no.
404 2022-06725. The FinnGen project is funded by two grants from Business Finland (HUS
405 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc.,
406 AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene
407 International II Sàrl), Genentech Inc., Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline
408 Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen
409 Biotech Inc, and Novartis AG. Following biobanks are acknowledged for delivering biobank
410 samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank
411 (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of
412 Northern Finland ([https://www.ppsHP.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-](https://www.ppsHP.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx)
413 [briefly-in-English.aspx](https://www.ppsHP.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx)), Finnish Clinical Biobank Tampere ([www.tays.fi/en-](http://www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere)
414 [US/Research_and_development/Finnish_Clinical_Biobank_Tampere](http://www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere)), Biobank of Eastern
415 Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank ([www.ksshP.fi/fi-](http://www.ksshP.fi/fi-FI/Potilaalle/Biopankki)
416 [FI/Potilaalle/Biopankki](http://www.ksshP.fi/fi-FI/Potilaalle/Biopankki)), Finnish Red Cross Blood Service Biobank
417 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank
418 (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks
419 are members of BBMRI.fi infrastructure (www.bbMRI.fi). Finnish Biobank Cooperative -FINBB

420 (<https://finbb.fi/>) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank
421 data can be accessed through the Fingenious[®] services (<https://site.fingenious.fi/en/>) managed by
422 FINBB.

423

424 **Author contributions**

425 JJ conceived the study plan and designed the proof outline. JKLM, CQ, JL and AK performed the
426 analyses. JJ, JL and SH were responsible of data acquisition. All authors contributed to the writing
427 of the manuscript and interpretation of the results. All authors listed under FinnGen contributed to
428 the generation of the primary data of the FinnGen data release 12. FinnGen authors are listed in the

429 **Supplementary Table 15.**

430

431 **Competing interests**

432 The authors declare no competing interests.

433 **References**

- 434 1. Clegg, A., Young, J., Iliffe, S., Rikkert, M. O. & Rockwood, K. Frailty in elderly people. *The*
435 *Lancet* **381**, 752–762 (2013).
- 436 2. Kojima, G., Iliffe, S. & Walters, K. Frailty index as a predictor of mortality: a systematic
437 review and meta-analysis. *Age Ageing* **47**, 193–200 (2018).
- 438 3. Theou, O., Brothers, T. D., Mitnitski, A. & Rockwood, K. Operationalization of Frailty Using
439 Eight Commonly Used Scales and Comparison of Their Ability to Predict All-Cause
440 Mortality. *J. Am. Geriatr. Soc.* **61**, 1537–1551 (2013).
- 441 4. Gilbert, T. *et al.* Development and validation of a Hospital Frailty Risk Score focusing on
442 older people in acute care settings using electronic hospital records: an observational study.
443 *Lancet Lond. Engl.* **391**, 1775–1782 (2018).
- 444 5. Young, A. C. M., Glaser, K., Spector, T. D. & Steves, C. J. The Identification of Hereditary
445 and Environmental Determinants of Frailty in a Cohort of UK Twins. *Twin Res. Hum. Genet.*
446 *Off. J. Int. Soc. Twin Stud.* **19**, 600–609 (2016).
- 447 6. Mak, J. K. L. *et al.* Sex differences in genetic and environmental influences on frailty and its
448 relation to body mass index and education. *Aging* **13**, 16990–17023 (2021).
- 449 7. Mak, J. K. L. *et al.* Genetic and Environmental Influences on Longitudinal Frailty
450 Trajectories From Adulthood into Old Age. *J. Gerontol. A. Biol. Sci. Med. Sci.* **78**, 333–341
451 (2023).
- 452 8. Atkins, J. L. *et al.* A genome-wide association study of the frailty index highlights brain
453 pathways in ageing. *Aging Cell* **20**, e13459 (2021).

- 454 9. Ye, Y. *et al.* A genome-wide association study of frailty identifies significant genetic
455 correlation with neuropsychiatric, cardiovascular, and inflammation pathways. *GeroScience*
456 **45**, 2511–2523 (2023).
- 457 10. Giambartolomeie, C. *et al.* Bayesian test for colocalisation between pairs of genetic
458 association studies using summary statistics. *PLoS* **10**(5):e1004383 (2014).
- 459 11. Rosoff, D. B. *et al.* Multivariate genome-wide analysis of aging-related traits identifies novel
460 loci and new drug targets for healthy aging. *Nat. Aging* **3**, 1020–1035 (2023).
- 461 12. Xie, Z. *et al.* Gene Set Knowledge Discovery with Enrichr. *Curr. Protoc.* **1**, e90 (2021).
- 462 13. Aslam, M. M. *et al.* Genome-wide analysis identifies novel loci influencing plasma
463 apolipoprotein E concentration and Alzheimer’s disease risk. *Mol. Psychiatry* **28**, 4451–4462
464 (2023).
- 465 14. Yeh, K.-H. *et al.* Genetic Variants at the APOE Locus Predict Cardiometabolic Traits and
466 Metabolic Syndrome: A Taiwan Biobank Study. *Genes* **13**, 1366 (2022).
- 467 15. Kemper, K. E. *et al.* Genetic influence on within-person longitudinal change in
468 anthropometric traits in the UK Biobank. *Nat. Commun.* **15**, 3776 (2024).
- 469 16. Bennet, A. M. *et al.* Pleiotropy in the presence of allelic heterogeneity: alternative genetic
470 models for the influence of APOE on serum LDL, CSF amyloid- β 42, and dementia. *J.*
471 *Alzheimers Dis. JAD* **22**, 129–134 (2010).
- 472 17. Willer, C. J. *et al.* Newly identified loci that influence lipid concentrations and risk of
473 coronary artery disease. *Nat. Genet.* **40**, 161–169 (2008).
- 474 18. Mak, J. K. L., Kuja-Halkola, R., Wang, Y., Hägg, S. & Jylhävä, J. Frailty and comorbidity in
475 predicting community COVID-19 mortality in the U.K. Biobank: The effect of sampling. *J.*
476 *Am. Geriatr. Soc.* **69**, 1128–1139 (2021).

- 477 19. Luster, A. D., Alon, R. & von Andrian, U. H. Immune cell migration in inflammation: present
478 and future therapeutic targets. *Nat. Immunol.* **6**, 1182–1190 (2005).
- 479 20. Zhang, L., Zeng, X., He, F. & Huang, X. Inflammatory biomarkers of frailty: A review. *Exp.*
480 *Gerontol.* **179**, 112253 (2023).
- 481 21. Sinnott-Armstrong, N. *et al.* Genetics of 35 blood and urine biomarkers in the UK Biobank.
482 *Nat. Genet.* **53**, 185–194 (2021).
- 483 22. Jansen, I. E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways
484 influencing Alzheimer’s disease risk. *Nat. Genet.* **51**, 404–413 (2019).
- 485 23. Karabulut, M. *et al.* Serum nectin-2 levels are diagnostic and prognostic in patients with
486 colorectal carcinoma. *Clin. Transl. Oncol. Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer*
487 *Inst. Mex.* **18**, 160–171 (2016).
- 488 24. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220 human phenotypes.
489 *Nat. Genet.* **53**, 1415–1424 (2021).
- 490 25. Giannisis, A. *et al.* Plasma apolipoprotein E levels in longitudinally followed patients with
491 mild cognitive impairment and Alzheimer’s disease. *Alzheimers Res. Ther.* **14**, 115 (2022).
- 492 26. Rasmussen, K. L., Tybjærg-Hansen, A., Nordestgaard, B. G. & Frikke-Schmidt, R. Plasma
493 levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in
494 105 949 individuals from a white general population cohort. *Eur. Heart J.* **40**, 2813–2824
495 (2019).
- 496 27. Fuior, E. V. & Gafencu, A. V. Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism
497 and Beyond. *Int. J. Mol. Sci.* **20**, 5939 (2019).
- 498 28. Yengo, L. *et al.* A saturated map of common genetic variants associated with human height.
499 *Nature* **610**, 704–712 (2022).

- 500 29. He, D. *et al.* A longitudinal genome-wide association study of bone mineral density mean and
501 variability in the UK Biobank. *Osteoporos. Int. J. Establ. Result Coop. Eur. Found.*
502 *Osteoporos. Natl. Osteoporos. Found. USA* **34**, 1907–1916 (2023).
- 503 30. Chernus, J. *et al.* GWAS reveals loci associated with velopharyngeal dysfunction. *Sci. Rep.* **8**,
504 8470 (2018).
- 505 31. Kurki, M. I. *et al.* FinnGen provides genetic insights from a well-phenotyped isolated
506 population. *Nature* **613**, 508–518 (2023).
- 507 32. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide
508 range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
- 509 33. Pärn, K. *et al.* Genotype imputation workflow v3.0. (2018).
- 510 34. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*
511 **562**, 203–209 (2018).
- 512 35. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in
513 large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).
- 514 36. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in
515 large cohorts. *Nat. Genet.* **47**, 284–290 (2015).
- 516 37. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity
517 in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 518 38. Dai, Y. *et al.* WebCSEA: web-based cell-type-specific enrichment analysis of genes. *Nucleic*
519 *Acids Res.* **50**, W782–W790 (2022).
- 520 39. Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for
521 taxonomy-based analysis of pathways and genomes. *Nucleic Acids Res.* **51**, D587–D592
522 (2023).

- 523 40. Milacic, M. *et al.* The Reactome Pathway Knowledgebase 2024. *Nucleic Acids Res.* **52**,
524 D672–D678 (2023).
- 525 41. Agrawal, A. *et al.* WikiPathways 2024: next generation pathway database. *Nucleic Acids Res.*
526 **52**, D679–D689 (2024).
- 527 42. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
- 528 43. Sun, B. B. *et al.* Plasma proteomic associations with genetics and health in the UK Biobank.
529 *Nature* **622**, 329–338 (2023).
- 530 44. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via Bayesian
531 regression and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).
- 532 45. Chou, W.-C. *et al.* A combined reference panel from the 1000 Genomes and UK10K projects
533 improved rare variant imputation in European and Chinese samples. *Sci. Rep.* **6**, 39313
534 (2016).
- 535

Table 1. Characteristics of the study samples.

Characteristic	FinnGen	UK Biobank
No. of individuals	519,200	429,463
Age at baseline assessment, mean (SD)	53.1 (17.9)	56.9 (8.0)
Age at end of follow-up/death, mean (SD)	60.8 (18.0)	70.8 (7.9)
Sex, n (%)		
Women	292,784 (56.4)	232,380 (54.1)
Men	226,416 (43.6)	197,083 (45.9)
BMI (kg/m ²), mean (SD)	27.35 (5.53)	27.41 (4.76)
Missing, n (%)	142,454 (27.4)	1348 (0.3)
Smoking, n (%)		
Non-smoker	156,355 (50.9)	232,968 (54.2)
Former smoker	70,317 (22.9)	151,248 (35.2)
Current smoker	80,736 (26.2)	43,776 (10.2)
Missing	211,792	1,471
HFRS, median (IQR)	5.2 (1.6–10.4)	1.5 (0–5)
Women, median (IQR)	5.3 (1.6–10.5)	1.5 (0–4.7)
Men, median (IQR)	5.0 (1.5–10.3)	1.5 (0–5.4)
HFRS categories, n (%)		
Low risk (<5)	241,656 (48.4)	320,961 (74.7)
Intermediate risk (5–15)	188,147 (37.8)	78,292 (18.2)
High risk (>15)	65,925 (13.2)	30,210 (7.0)
HFRS >5, n (%)	254,874 (51.0)	106,645 (24.8)
HFRS >5 before age 65, n (%)	95,410 (18.4)	35,556 (8.3)
Died during follow-up, n (%)	62,764 (12.1)	38,636 (9.0)
Time to mortality follow-up (year), median (IQR)	4.4 (2.6–8.5)	14.4 (13.6–15.0)
Number of hospitalizations, median (IQR)	8 (4–17)	1 (0–3)

Note. FinnGen participant characteristics are presented for the sample with non-missing phenotypic data (N=519,200).

BMI, body mass index; HFRS, Hospital Frailty Risk Score; IQR, interquartile range; SD, standard deviation.




Figure 1. Outline of the study. GWAS, genome-wide association study; HFRS, Hospital Frailty Risk Score; ICD-10, International Classification of Diseases, 10th Revision; PRS, polygenic risk score




Figure 2. Manhattan plots for the associations with **(a)** Hospital Frailty Risk Score (HFRS) and **(b)** HFRS excluding dementia in FinnGen. The dashed lines indicate the genome-wide significance threshold ($p=5 \times 10^{-8}$). The annotations represent the strongest signals in genes containing potentially functional variants ($p < 5 \times 10^{-7}$) associated with frailty; red font indicates genes that include variants previously unreported in the GWAS Catalog or previous GWASs of frailty.




Figure 3. Novel genes and genetic correlations of the with other related traits. **(a)** Venn diagram showing the overlap of genes associated with the full HFRS and the HFRS without dementia at $p < 5 \times 10^{-8}$ in FinnGen and those reported in the literature. Previous GWASs refers to genes identified in for the FI (Atkins et al., 2021), FP (Ye et al., 2023), and mvAge (Rosoff et al., 2023). **(b)** Genetic correlations between HFRS in FinnGen and other frailty-related traits. All the correlations were statistically significant at $p < 2.2 \times 10^{-16}$. FI, frailty index, FP, frailty phenotype; GWAS, genome-wide association study; HFRS, Hospital Frailty Risk Score; PRS, polygenic risk score




Figure 4. Protein associations with the (a) full HFRS and (b) HFRS without dementia the in UK Biobank using linear regression models. All models were adjusted for birth year, sex, and the first 10 principal components. Solid dots indicate significant associations at a false discovery rate <0.05. HFRS, Hospital Frailty Risk Score; SD, standard deviation




Figure 5. Associations of the HFRS-PRS with the HFRS (a), early-onset frailty (b), all-cause mortality and number of hospitalizations (d) in FinnGen and UK Biobank. All models included birth year, birth region, sex, smoking and first 10 principal components as covariates. HFRS, Hospital Frailty Risk Score; HR, hazard ratio; OR, odds ratio; PRS, polygenic risk score; SD, standard deviation.